Phase 1 Study Of Lentivirally Transduced T Cells Engineered To Contain Anti-CD123 In Subjects With Refractory Or Relapsed Acute Myeloid Leukemia

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

12 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia (AML). Main study procedures include medical record review, apheresis, CART123 infusion, blood draws, physical exams, imaging, and disease assessments through bone marrows and lumbar punctures. If interested in the study or if you have any questions, please contact 267-426-0762.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at khanr [at] chop.edu or 215-590-5476.

Eligibility & Criteria

IRB #:
19-016468
Official Title:
Phase 1 Study Of Lentivirally Transduced T Cells Engineered To Contain Anti- CD123 Linked To TCR And 4-1BB Signaling Domains In Pediatric Subjects With Refractory Or Relapsed Acute Myeloid Leukemia
Study Phase:
Phase I
Eligible Age Range:
1 - 21 Years
Gender:
All
Study Categories:
Leader
Richard Aplenc

Richard Aplenc, MD, PhD, MSCE